ArticleBreast cancer (Tokyo, Japan)2026
Pathologic complete response and survival according to germline BRCA1/2 status in triple-negative breast cancer.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGermline BRCA1/2 pathogenic variants (gBRCA-PV) are associated with chemosensitivity in triple-negative breast cancer (TNBC), but whether higher pathologic complete response (pCR) rates translate into improved long-term outcomes remains uncertain. We assessed associations of gBRCA-PV status with pCR, recurrence-free survival (RFS) and breast cancer-specific survival (BCSS) in a real-world TNBC cohort treated with neoadjuvant chemotherapy (NACT).
methodsWe retrospectively analyzed 293 patients with stage I-III TNBC diagnosed between 2007 and 2023 who were treated with NACT and underwent germline BRCA1/2 testing at a single tertiary center. Multivariable logistic and Cox regression models assessed pCR, RFS and BCSS.
resultsOf 293 patients, 56 (19.1%) carried gBRCA-PV. The overall pCR rate was 49.5% and was higher in carriers than noncarriers (73.2% vs. 43.9%, p<0.001). After adjustment for age at diagnosis, clinical stage, NACT regimen, noncarriers had lower odds of pCR (OR 0.36, 95% CI 0.18-0.70, p=0.004). In Cox models, associations between gBRCA-PV status and RFS or BCSS did not reach statistical significance, either with or without adjustment for pCR, and estimates were imprecise. pCR was strongly associated with improved RFS (HR 0.24) and BCSS (HR 0.20) (both p<0.001).
conclusionsgBRCA-PV carriers were more likely to achieve pCR after NACT, whereas associations with RFS or BCSS remained uncertain. The limited number of events and wide confidence intervals preclude firm conclusions regarding survival differences. Larger cohorts with longer follow-up are needed to clarify the relationship between gBRCA status, treatment response and long-term outcomes.
Indexed as
Identifiers
42720862What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.